1st Sep 2014 07:52
LONDON (Alliance News) - AstraZeneca PLC said Monday results from a Phase IV study of its Brilinta/Brilique treatment for ST segment elevation myocardial infarction patients show it can be initiated in pre-hospital or in hospital.
AstraZeneca said the study showed that the treatment has the flexibility to be used safely in either setting, with a potential benefit on the early occurrence of stent thrombosis.
The study, which the company called ATLANTIC, evaluated the treatment in pre-hospital and in-hospital settings. Results showed there was no statistically significant difference between the pre-hospital or in-hospital study arms in its co-primary endpoints.
The study was not empowered to look at clinical outcomes, AstraZeneca said. However, there was no difference between the two study arms in terms a composite endpoint. It also said that the results showed no difference in bleeding events between the two study arms, the primary safety endpoint of the study.
AstraZeneca will present data from the study at the European Society of Cardiology Congress currently under way in Barcelona.
Shares in AstraZeneca were trading down 0.6% at 4,538.00 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca